Pills, pricing and growth

Warfarin, toxin of choice to rid us of nasty rats, is also the drug of choice to stop you having a blood clot. Liberally prescribed on the NHS, the tablets cost peanuts. However it’s not perfect. You can’t take it with other common medicines such as aspirin and thyroxine, you can’t eat your greens (spinach, Brussels sprouts, Swiss chard, green beans, asparagus, broccoli etc) and it requires regular blood tests to ensure the dose is ok. These checks also cost the NHS money – in some cases patient’s require weekly appointments with a nurse.

So that’s why companies have been trying to find something better.  Pfizer and BMS have just produced more  results from their contribution. They are not the only ones, but the point is, it will be much more expensive than warfarin, so will our doctors prescribe it even though it will reduce staff costs? And how will patients know to ask for it? Will the government be giving power as well as information?

Meanwhile in Germany, a new drug for Diabetes is sitting on the shelf because changes to the government’s pricing mechanism mean that the proposed price could be so low it might not be worth the producers selling it there. The repercussions are huge: loss of revenue for the company; no access to the medicine for patients; loss of clinical trials opportunities in the future (as new medicines are compared the best in field); an implicit message to industry that innovation isn’t valued.

There are important reasons to remember that there is more to medicines than taking a pill: ensuring we don’t disincentivise risk-taking and the innovative steps that can turn into a breakthrough; offering choice; remembering that although drug development is global, without a strong science base and a fair market we will lose out both economically and medically. If George Osborne is serious about science and innovation being the priority for growth (and the Life Sciences Autumn Package questions are taken seriously), then he also mustn’t ignore DH plans for changes to pricing of medicines. They might not think that pills, pricing and growth are connected, but believing them would risk our recovery.



About Julia Manning

Julia is a social pioneer, writer and campaigner. She studied visual science at City University and became a member of the College of Optometrists in 1991, later specialising in visual impairment and diabetes. During her career in optometry, she lectured at City University, was a visiting clinician at the Royal Free Hospital and worked with Primary Care Trusts. She ran a domiciliary practice across south London and was a Director of the UK Institute of Optometry. Julia formed 20/20Health in 2006. Becoming an expert in digital health solutions, she led on the NHS–USA Veterans’ Health Digital Health Exchange Programme and was co-founder of the Health Tech and You Awards with Axa PPP and the Design Museum. Her research interests are now in harnessing digital to improve personal health, and she is a PhD candidate in Human Computer Interaction (HCI) at UCL. She is also dedicated to creating a sustainable Whole School Wellbeing Community model for schools that builds relationships, discovers assets and develops life skills. She is a member of the Royal Society of Medicine’s Digital Health Council. Julia has shared 2020health's research widely in the media (BBC News, ITV, Channel 5 News, BBC 1′s The Big Questions & Victoria Derbyshire, BBC Radio 4 Today, PM and Woman's Hour, LBC) and has taken part in debates and contributed to BBC’s Newsnight, Panorama, You and Yours and ITV’s The Week.
This entry was posted in Business, Drugs, Innovation, Uncategorized and tagged , , , , , , . Bookmark the permalink.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s